title: Alogliptin: a review of its use in patients with type 2 diabetes mellitus.
abstract: The dipeptidyl peptidase-4 inhibitor alogliptin (Nesina®, Vipidia®) is approved in numerous countries worldwide for the treatment of type 2 diabetes mellitus. Fixed-dose combinations of alogliptin/metformin (Kazano®, Vipdomet®) and alogliptin/pioglitazone (Oseni®, Incresync®) are also available. This article reviews the clinical efficacy and tolerability of oral alogliptin in the treatment of type 2 diabetes. Results of randomized controlled trials demonstrated that oral alogliptin improved glycaemic control when administered as monotherapy, as dual therapy in combination with metformin, pioglitazone, a sulfonylurea, voglibose or insulin, or as triple therapy in combination with metformin plus pioglitazone. Alogliptin was generally well tolerated in patients with type 2 diabetes and was weight neutral, with a low risk of hypoglycaemia. Results of the large, well designed EXAMINE trial revealed that alogliptin was not associated with an increased risk of major cardiovascular events in patients with type 2 diabetes and recent acute coronary syndrome. In conclusion, alogliptin is a useful option for the treatment of patients with type 2 diabetes.
authors: Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand, demail@springer.com.
authors: Gillian M
authors: GM
authors: Keating
mesh_terms: D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination / Q000379:methods; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D010880:Piperidines / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D014498:Uracil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D007004:Hypoglycemic Agents; D010880:Piperidines; D014498:Uracil; C520853:alogliptin